Actos is owned by Takeda Pharms Usa.

Actos contains Pioglitazone Hydrochloride.

Actos has a total of 10 drug patents out of which 10 drug patents have expired.

Expired drug patents of Actos are:

• US6166043
• US6150384
• US6166042
• US6150383
• US5965584
• US6271243
• US6329404
• US6172090
• US6211205
• US6303640

Actos was authorised for market use on 15 July, 1999.

Actos is available in tablet;oral dosage forms.

Actos can be used as a method of treating lipid metabolism disorders by administering a chemical compound having a particular formula (which includes pioglitazone) in combination with an insulin secretion enhancer, as an adjunct to diet and exercise to improve glycemic control in patients with type 2 diabetes, a method for reducing the amount of active components administered to a diabetic patient by administering an insulin sensitivity enhancer (including pioglitazone) in combination with a biguanide as said active components, a method for reducing side effects of active components administered to a diabetic patient by administering an insulin sensitivity enhancer (including pioglitazone) in combination with a biguanide as said active components, method of reducing side effects of active components admin to a diabetic by admin a chemical compound having formula (incl pioglitazone) in combination with an insulin secretion enhancer, a method of treating glycometabolism disorders by administering an insulin sensitivity enhancer (including pioglitazone) in combination with a biguanide, method of reducing amount of respective active components administered to a diabetic patient by administering a chemical compound having a particular formula (including pioglitazone) in combination with an insulin secretion enhancer, method of reducing the side effects of active components administered to a diabetic patient by administering a chemical compound having a particular formula (which includes pioglitazone) in combination with an insulin preparation, a method of treating lipid metabolism disorders by administering an insulin sensitivity enhancer (including pioglitazone) in combination with a biguanide.

The generics of Actos are possible to be released after 09 August, 2016.